Abstract |
A new in vitro anti- tumor polypeptide, coded as J2-C3, was isolated from Arca inflata Reeve and purified by diethyl-aminoethanol ( DEAE)- sepharose Fast Flow anion exchange and phenyl sepharose CL-4B hydrophobic chromatography. J2-C3 was identified to be a homogeneous compound by native polyacrylamide gel electrophoresis (Native-PAGE). The purity of J2-C3 was over 99% in reversed phase-high performance liquid chromatography (RP-HPLC). The molecular weight was determined as 20,538.0 Da by electrospray-ionization mass spectrometry (ESI-MS/MS). J2-C3 was rich in Glx (Gln + Glu), Lys, and Asx (Asp + Asn) according to amino acid analysis. Four partial amino acid sequences of this peptide were determined as L/ISMEDVEESR, KNGMHSI/LDVNHDGR, AMKI/LI/LNPKKGI/LVPR and AMGAHKPPKGNEL/IGHR via MALDI-TOF/TOF-MS and de novo sequencing. Secondary structural analysis by CD spectroscopy revealed that J2-C3 had the α-helix (45.2%), β-sheet (2.9%), β-turn (26.0%) and random coil (25.9%). The anti- tumor effect of J2-C3 against human tumor cells was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and the IC₅₀ values of J2-C3 were 65.57, 93.33 and 122.95 µg/mL against A549, HT-29 and HepG2 cell lines, respectively. Therefore, J2-C3 might be developed as a potential anti- tumor agent.
|
Authors | Jian Xu, Zhiyan Chen, Liyan Song, Lili Chen, Jianhua Zhu, Shuangshuang Lv, Rongmin Yu |
Journal | Marine drugs
(Mar Drugs)
Vol. 11
Issue 12
Pg. 4773-87
(Dec 02 2013)
ISSN: 1660-3397 [Electronic] Switzerland |
PMID | 24317469
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Amino Acids
- Antineoplastic Agents
- Peptides
|
Topics |
- Amino Acid Sequence
- Amino Acids
(chemistry)
- Antineoplastic Agents
(chemistry, isolation & purification, pharmacology)
- Cell Line, Tumor
- HT29 Cells
- Hep G2 Cells
- Humans
- Molecular Weight
- Peptides
(chemistry, isolation & purification, pharmacology)
|